Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Condition: Ovarian Cancer Intervention: Drug: Pamiparib/Tamoxifen Sponsor: Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Ovarian Cancer | Ovaries | Research | Study | Tamoxifen | Toxicology